Lung cancer management during the COVID-19 pandemic: experience of a medical oncology unit at a tertiary hospital in Singapore

Abstract

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organisation (WHO) on 11 March 2020. The pandemic has had profound effects on healthcare systems across the world, and also poses unique challenges for oncology services. Singapore saw its first imported case of COVID-19 on 23 January 2020, and there has since been 52,000 confirmed cases and 27 deaths as of early August 2020 locally. Oncologists have a special duty to our patients to ensure patient safety and provide optimum care without undue disruption which may compromise long-term cancer-specific outcomes. We herein examine the impact that the COVID-19 pandemic has had on our clinical services, and share our experience with regards to manpower reconfiguration, infection control measures, diagnostic evaluation of patients with suspected COVID-19, oncological management of lung cancer patients, as well as changes in the education and training of juniors, from our unique position as a Medical Oncology department in Tan Tock Seng Hospital, a tertiary hospital affiliated with the National Centre of Infectious Diseases in Singapore.

Keywords

COVID-19 / lung cancer / thoracic cancer

References

[1] Johns HOpkins UNiversity and Medicine coronavirus resource centre mortality analyses 2020. Available from: https://coronavirus.jhu.edu/data/mortality. [Last accessed on 8 Dec 2020]

[2] Beigel JH,Dodd LE.Remdesivir for the treatment of Covid-19- preliminary report..N Engl J Med2020;383:994

[3] Group RC,Lim WS.Dexamethasone in hospitalised patients with Covid-19 - preliminary report..N Engl J Med2020;NEJMoa2021436: PMCID:PMC7383595

[4] gov.sg. What do the different DORSCON levels mean 2020. Available from: https://www.gov.sg/article/what-do-the-different-dorscon-levels-mean. [Last accessed on 8 Dec 2020]

[5] National centre for infectious diseases (NCID). About NCID. Available from: https://www.ncid.sg/About-NCID/Pages/default.aspx. [Last accessed on 8 Dec 2020]

[6] Urun Y,Bakouny Z.Survey of the impact of COVID-19 on Oncologists’ decision making in cancer..JCO Glob Oncol2020;6:1248-57 PMCID:PMC7456315

[7] London JW,Palchuk MB,McNair C.Effects of the COVID-19 pandemic on cancer-related patient encounters..JCO Clin Cancer Inform2020;4:657-65 PMCID:PMC7444638

[8] Maringe C,Morris M.The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study..Lancet Oncol2020;21:1023-34 PMCID:PMC7417808

[9] Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. [Last accessed on 8 Dec 2020]

[10] Wu ZY.Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention..JAMA2020;323:1239-42

[11] National University Cancer Institute of Singapore Workflow TA segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore..Ann Oncol2020;31:840-3 PMCID:PMC7174823

[12] Tan BF,Yap SP,Wang MLC.Managing the COVID-19 pandemic as a national radiation oncology centre in Singapore..Clin Oncol (R Coll Radiol)2020;32:e155-9 PMCID:PMC7177121

[13] Desai A,Parekh T.COVID-19 and cancer: lessons fom a pooled meta-analysis..JCO Glob Oncol2020;6:557-9 PMCID:PMC7193801

[14] Kuderer NM,Shah DP.Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study..Lancet2020;395:1907-18 PMCID:PMC7255743

[15] Lee LYW,Starkey T.COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study..Lancet2020;395:1919-26 PMCID:PMC7255715

[16] Solodky ML,Russias B.Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19..Ann Oncol2020;31:1087-8 PMCID:PMC7252166

[17] Garassino MC,Huang LC.COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study..Lancet Oncol2020;21:914-22 PMCID:PMC7292610

[18] Luo J,Preeshagul IR.COVID-19 in patients with lung cancer..Ann Oncol2020;31:1386-96 PMCID:PMC7297689

[19] Shi HS,Jiang NC.Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study..Lancet Infect Dis2020;20:425-34 PMCID:PMC7159053

[20] Guckenberger M,Bezjak A.Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement..Radiother Oncol2020;146:223-9 PMCID:PMC7252074

[21] Dingemans AC,Jazieh AR.Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic..J Thorac Oncol2020;15:1119-36 PMCID:PMC7227539

[22] National Comprehensive Cancer NetworkShort-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic..JCO Oncology Practice2020;16:579-86

[23] Curigliano G,Cervantes A.Managing cancer patients during the COVID-19 pandemic: an ESMO interdisciplinary expert consensus..Ann Oncol2020;31:1320-35

[24] ESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer 2020 16/08/2020. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/lung-cancer-in-the-covid-19-era. [Last accessed on 8 Dec 2020]

[25] Passaro A,Von Garnier C.ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer..ESMO Open2020;5:e000820 PMCID:PMC7319703

[26] Ternyila D. Recommendations for managing patients with lung cancer during COVID-19 Era: Targeted Oncology; 2020 Available from: https://www.targetedonc.com/view/recommendations-for-managing-patients-with-lung-cancer-during-covid-19-era. [Last accessed on 8 Dec 2020]

[27] Sia CH,Ooi SBS.Impact of the coronavirus disease 2019 pandemic on postgraduate medical education in a Singaporean academic medical institution..Korean J Med Educ2020;32:97-100 PMCID:PMC7272375

[28] Sidpra J,Reddy N,Mirsky D.Sustaining education in the age of COVID-19: a survey of synchronous web-based platforms..Quant Imaging Med Surg2020;10:1422-7 PMCID:PMC7358414

[29] Byrnes KG,Dunne CP,Coffey JC.Communication, collaboration and contagion: “Virtualisation” of anatomy during COVID-19..Clin Anat2020;34:82-89 PMCID:PMC7404681

[30] Wong CS,Hap XF.Love in the time of coronavirus: training and service during COVID-19..Singapore Med J2020;61:384-6

[31] Corbett KS,Leist SR.SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness..bioRxiv2020;145920: PMCID:PMC7301911

[32] Jackson LA,Rouphael NG.An mRNA vaccine against SARS-CoV-2 - preliminary report..N Engl J Med2020;383:1920-31 PMCID:PMC7377258

[33] Tai WB,Drelich A.A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2..Cell Res2020;30:932-935 PMCID:PMC7403570